Jupiter Neurosciences, Inc.

NASDAQ: JUNS · Healthcare · Biotechnology

PublicHQ Jupiter, FL · Palm BeachCIK 0001679628Reports USD

#1111 of 1,418 Healthcare companies by revenue

EA Score

18D

FH 22DQ 10GM —SS 22

v0.1 · 55/100 weight · provisional

↑ Piotroski F, market scale · ↓ disclosure history, operating margin

Methodology →

Revenue TTM

$64.7k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$8.6M

Employees

as of 2026-08-23

Market cap

$3.0M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$21.8k$21.8k2025

Net income-$8.6M-$8.6M2025

Operating income-$8.9M-$8.9M2025

Total assets$5.6M$5.6M2025

Liabilities$7.4M$7.4M2025

Equity-$1.8M-$1.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Jupiter Neurosciences, Inc.’s revenue?

Jupiter Neurosciences, Inc. booked $21.8k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -39662.8% net margin.

Peers · Healthcare

Sirona Biochem Corp.——Doseology Sciences Inc.40D Senti Biosciences, Inc.27D Skinvisible, Inc.29D South American Gold Corp.——THC Farmaceuticals, Inc.——

Neighbors

Palm Beach →

NextEra Energy, Inc.$25.8B77B+Monolithic Power Systems, Inc.$2.8B82B+Carrier Global Corporation$21.7B63C SBA Communications Corporation$244.5M66B Dycom Industries, Inc.$5.5B70B Celsius Holdings, Inc.$2.5B63C

Key facts

CEOChrister Rosen

SectorHealthcare

IndustryBiotechnology

HeadquartersJupiter, FL

ExchangeNASDAQ: JUNS

Employees5

IPO date2022-01-18

Latest filings

8-K2026-08-28 8-K2026-08-27 8-K2026-08-24 8-K2026-08-24 10-Q2026-08-14 8-K2026-08-06 8-K2026-07-28 8-K2026-07-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.